NextCure, Inc. (NXTC)
| Previous close | 1.2100 |
| Open | 1.2000 |
| Bid | 0.8568 x 200 |
| Ask | 1.5600 x 200 |
| Day's range | 1.2000 - 1.2000 |
| 52-week range | 0.9800 - 2.5700 |
| Volume | |
| Avg. volume | 300,316 |
| Market cap | 33.484M |
| Beta (5Y monthly) | 0.39 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.2500 |
| Earnings date | 02 May 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.00 |
GlobeNewswireNextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024
BELTSVILLE, Md., April 24, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that clinical trial investigator Eric S. Christenson, M.D., Assistant Professor of Oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, will present a poster on clinical data from the Phase 1b portion of a study evaluating NC410 in com
- GlobeNewswire
NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024
Poster presentation highlights strong safety and pharmacokinetic profiles for LNCB74BELTSVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the presentation of new preclinical data on LNCB74, a B7-H4-targeting antibody drug conjugate (ADC) developed in partnership with LigaChem Biosciences (LCB), formerly
- GlobeNewswire
NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board
BELTSVILLE, Md., April 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the appointment of Rakesh Dixit, PhD, to its Scientific Advisory Board. As an accomplished product developer whose expertise is focused on antibody-drug conjugates (ADCs), Dr. Dixit will support NextCure in its efforts to build and develop its proprie
